Cosmos Health’s distribution arm, Cosmofarm, is accelerating its build-out in Greece. In 2025, the wholesaler added nearly 100 new pharmacy customers, lifting its active base by roughly 20%, while improving annual revenue per customer by about 12% and profitability per customer by approximately 14%. To support demand and service levels, Cosmofarm introduced three additional delivery routes across Attica and is expanding automation with Rowa and A-frame robotic systems. A new capital program of about $1 million is underway to increase throughput, backed by upgrades to a 29,000-square-foot Athens facility with expanded distribution space and enhanced temperature-controlled storage. The company targets roughly $40 million in incremental annual revenue capacity as these investments come online.
The strategic question is whether last-mile excellence can become a competitive moat in a margin-compressed European market. Greece’s pharmacy channel remains fragmented and price-regulated, pushing distributors to find efficiency gains wherever possible. By densifying routes and scaling robotics, Cosmofarm is positioning distribution reliability—not just price—as the lever to win share and attract launch partners. For manufacturers weighing direct-to-pharmacy versus traditional models in smaller EU markets, a tech-enabled wholesaler with higher fill rates and cold-chain fidelity can tip the balance in favor of new brand deployments and exclusivity agreements.
This matters now because supply volatility has become a permanent planning variable. GLP-1s, oncology injectables, and other constrained categories have exposed weak points in local fulfillment and inventory visibility. For patients and pharmacists, increased delivery frequency in Attica promises fewer stockouts and more predictable access, especially for temperature-sensitive therapies. For payers, better inventory signals and on-time delivery can support substitution policies, adherence programs, and budget predictability. For competing wholesalers and parallel traders, increased robotic capacity and route density raise the bar on service-level differentiation, compressing room for arbitrage while shifting competition toward data, cold-chain execution, and value-added services.
Cosmofarm’s moves reflect a broader European trend: wholesalers investing in automation to defend margins and to support the growing share of specialty and biologic products in the retail channel. Robotics and integrated WMS platforms bring accuracy, speed, and traceability—capabilities increasingly required by manufacturers seeking serialized control and by regulators looking to mitigate shortages. The infrastructure also creates commercial adjacencies: pharmacy-level insights, real-time inventory analytics, and readiness for patient support program logistics. For Medical Affairs teams, more granular distribution data and temperature tracking can enable better detection of pharmacovigilance signals and the generation of RWE on initiation, persistence, and switch behavior in community settings.
The next test is conversion. Capacity does not equal contracts. To translate infrastructure into durable economics, Cosmos Health will need to secure preferred or exclusive distribution for select brands, demonstrate measurable improvements in on-shelf availability for high-demand therapies, and offer data services that help manufacturers optimize demand planning and payer negotiations. With a footprint that spans Greece and the UK, the company could angle for cross-market launch packages, but execution will hinge on service KPIs, cold-chain performance, and the ability to integrate with manufacturer PSPs and outcomes-based arrangements.
If supply stability is the new currency of trust in European retail pharma, Cosmofarm has bought an option on leadership. The open question for 2026 is whether it can leverage this upgraded platform to win specialty distribution mandates—and monetize the data exhaust—to become not just a faster wholesaler, but a strategic launch partner in a high-variance market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
